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339which is lower than the overall surgical mortality of 0.13% (1). The
causation of erosion, based on review of reports available, is still
unclear, and we proposed a few possible risk factors for erosion in
our paper. To further deﬁne individual risk factors for erosion with
the Amplatzer septal occluder (St. Jude Medical, St. Paul, Min-
nesota), a very large, detailed, longitudinal dataset will be required.
The IMPACT (Improving Pediatric and Adult Congenital
Treatments) registry, although currently not suitable for longitu-
dinal studies, could be adapted to evaluate device closures of atrial
septal defect across nearly 100 centers in the United States and
Canada (1). A similar registry would be needed to gather data on
patients outside of the United States to further our understanding
of this subject.
We need to gather more data before making any radical changes
to current post–device-closure surveillance practices. The interim
recommendations proposed by the U.S. Food and Drug Admin-
istration panel could be modiﬁed as more data becomes available to
include recommendations such as stress echocardiography and re-
striction of physical activity, as proposed by Santini et al. (2).
The rarity of the event, lack of adequate high-quality data, and
the unpredictability of the timeline to erosion make it very difﬁcult
to propose deﬁnitive recommendations for now.
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I was very interested to read the paper by Wilson et al. (1), relating
to achieving sustainable door-to-balloon (D2B) times of 90 min for
regional transfer of ST-segment elevation myocardial infarction
(STEMI) patients, and I have a few comments.First, I would like to congratulate the authors for accom-
plishing this task, which in my opinion is not easy to do.
Second, the outcome of this investigation is D2B <90 min
from the time the patient entered the transferring hospital,
but I could not detect any clinical outcome results of this
accomplishment.
Despite the fact that the D2B metric of <90 min was
accomplished, as far as I could tell, nothing is mentioned in
the paper relating to 30-day readmission rate, 30-day mortality,
or 1-year mortality. The investigators do note that despite their
accomplishments, length of stay and in-hospital mortality
remained unchanged, compared with longer D2B times in the
past.
I do not think there is any question that D2B is a metric, but can
we honestly say that it is the only metric that should be measured to
evaluate outcome in patients with acute STEMI?
I doubt that the investigators will be able to get this information,
but it would be nice if they had some data on the duration of
symptoms to balloon (S2B), because I suspect the duration of
symptoms may play a role in outcome. Similarly, patients with a
history of prior myocardial infarction are more likely to have a
poorer outcome than those who have a ﬁrst infarction. Along the
same lines, current smokers and patients with renal dysfunction
may be more likely to have a negative outcome than those who do
not have these risk factors.
It would also be interesting to know whether or not there is a
difference in outcome in females and males.
In my opinion, there is no question that D2B is an important
metric, but it is not the only metric that affects outcome in STEMI
patients (2). Outcome studies in STEMI patients that do not
include these other metrics do not take into consideration the risk
proﬁle of the individual patient and may overestimate successful
interventions in these high-risk groups.
Current STEMI therapy focuses on early reperfusion of the
infarct-related artery, with the goal of a D2B time of <90 min. The
investigators have accomplished that goal but have not considered
other metrics that might inﬂuence outcome.
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